Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REQUIP IR-controlled n-of-1 crossover pilot trial of REQUIP CR for daytime somnolence in Parkinson's disease
2009-012529-12Phase 4Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ropinirole prolonged release and ropinirole in Parkinson's disease (PD) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Subjective discomfort induced by daytime somnolence. Started May 2009; status: active.
02
Drugs
ropinirole prolonged releaseropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-012529-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012529-12.